Danish Biotech Stock News

Expanded UK hospital contract shifts attention to ISS (CPSE:ISS) ISS (CPSE:ISS) has expanded its agreement with the Fulham Road Collaborative in the UK, adding a DKK 100 million per year, five-year facility services contract across three major hospital sites. See our latest analysis for ISS. The expanded UK hospital contract arrives while ISS shares trade at DKK238.6, with a 7 day share price return of 4.56% and year to date share price return of 10.67%, alongside a 1 year total shareholder...

Coloplast (CPSE:COLO B) has come back into focus after Biatain Silicone Fit received an Innovative Technology contract from Vizient in the US, shortly after the company lowered its earnings guidance for 2025/26. See our latest analysis for Coloplast. Coloplast shares trade at DKK402.8 after a 1 day share price return of 2.26%. However, the 30 day share price return of 9.03% decline and 1 year total shareholder return of 39.94% decline indicate that momentum has been weak despite the recent...

DSV A/S ( CPH:DSV ) shareholders are probably feeling a little disappointed, since its shares fell 6.4% to kr.1,571 in...

Recent geopolitical tensions that earlier led to the closure of the Strait of Hormuz and instability in the Red Sea have forced container carriers such as A.P. Møller - Mærsk to reroute traffic, turning Africa and ports like Saudi Arabia’s Jeddah into new hubs amid longer transit times and congestion. This reshaping of trade lanes underlines how regional ports such as Sohar, Khorfakkan, Fujairah and Jeddah can quickly gain influence when core shipping corridors are disrupted. We’ll now...

While HusCompagniet A/S ( CPH:HUSCO ) might not have the largest market cap around , it received a lot of attention...

ALK-Abelló (CPSE:ALK B) reported positive topline phase 2 results for its once daily sublingual immunotherapy tablet targeting peanut allergy. The trial results indicated clinically meaningful efficacy and a favorable safety profile across a broad age range of participants. This peanut allergy candidate expands ALK-Abelló’s pipeline beyond its existing allergy tablet portfolio. For investors tracking ALK-Abelló, the phase 2 readout arrives with the share price at DKK242.0 and a 1 year...

Novo Nordisk has launched an oral version of Ozempic across the US, moving its GLP-1 franchise beyond injectable formats. The pill is being rolled out through more than 70,000 pharmacies, along with telehealth, GoodRx, and Weight Watchers partnerships. This broader distribution approach is intended to widen patient access and adjust the company’s GLP-1 strategy in response to competitive and regulatory pressures. Novo Nordisk, traded as CPSE:NOVO B, now has this new oral Ozempic launch...

How AL Sydbank’s recent return profile looks after a strong year AL Sydbank (CPSE:ALSYDB) has drawn attention after a solid 1 year total return of 33.5%, set against mixed shorter term moves. These include a monthly gain of 2.4% and a decline of 3.9% over the past 3 months. See our latest analysis for AL Sydbank. At a share price of DKK549.0, recent trading suggests momentum has cooled in the short term, even as longer term total shareholder returns remain strong. This can reflect shifting...

As of late April 2026, European markets have been navigating a challenging landscape marked by geopolitical tensions and fluctuating economic indicators. Despite these hurdles, opportunities abound for investors willing to explore beyond the mainstream indices. Penny stocks, though often considered niche investments, can offer intriguing growth potential when they are backed by sound financial fundamentals. In this article, we will examine three European penny stocks that stand out for their...

Danske Bank (CPSE:DANSKE) has opened Q1 2026 earnings season with Q4 2025 revenue of DKK 15.2b and basic EPS of DKK 7.72, set against trailing 12 month EPS of DKK 27.94 and revenue of DKK 56.5b and a reported decline in earnings over the last year following several years of strong average growth. Over recent quarters, revenue has moved from DKK 14.7b in Q4 2024 to DKK 15.2b in Q4 2025, while quarterly EPS has ranged between DKK 6.56 and DKK 7.72 as trailing net profit margin eased from 41.5%...

Why the Supreme Court ruling matters for Tryg The Danish Supreme Court’s new workers’ compensation ruling has put Tryg (CPSE:TRYG) in focus as the insurer recognises a one off DKK 1.2b pre tax impact tied to historical cases. At the same time, Tryg and the Danish Insurance Association expect the Danish State to indemnify the industry for this loss. This is a key point for investors weighing legal risk against the insurer’s capital position. See our latest analysis for Tryg. Tryg’s share price...

Alm. Brand Q1 2026 earnings snapshot Alm. Brand (CPSE:ALMB) has followed up its recent Q4 2025 result with total revenue of DKK 3.98b and basic EPS of DKK 0.23, supported over the last 12 months by a net profit margin of 8.2% versus 5.7% in the prior period. Over recent quarters the company has seen revenue range between DKK 3.26b and DKK 3.98b, while quarterly basic EPS has moved between DKK 0.11 and DKK 0.23, alongside trailing EPS growth of 49.3% year over year. Taken together, these...

DSV (CPSE:DSV) opened 2026 with Q1 results anchored by prior quarter revenue of about DKK71.7b and basic EPS of DKK4.72, set against trailing 12 month revenue of roughly DKK247.3b and EPS of DKK35.57. Over recent quarters, revenue has moved from about DKK43.5b in Q4 2024 to the DKK71.7b level in Q4 2025, while quarterly EPS shifted from DKK9.46 to DKK4.72, leaving investors focused on how much of the top line is converting into sustainable margins. See our full analysis for DSV. With the...

Ringkjøbing Landbobank (CPSE:RILBA) has put up another solid scorecard, with trailing twelve month revenue of DKK4.2b and basic EPS of DKK92.86 framing the latest Q1 2026 update, while reported net profit margin sits at 55.7% versus 55.6% a year earlier. Over recent quarters, the bank has seen quarterly revenue move in a tight band between DKK1,003.19m and DKK1,073.47m and basic EPS range from DKK20.68 to DKK23.87, giving investors a clear earnings profile supported by firm margins rather...

Embla Medical hf (CPSE:EMBLA) has opened 2026 with Q1 revenue of US$232.4 million and basic EPS of US$0.034, setting the tone for how its earnings story is evolving against a current share price of DKK26.9. Over the past year, the company has seen trailing twelve month revenue move from US$854.9 million to US$958.3 million while basic EPS on the same basis went from US$0.160 to US$0.202. This gives investors a clearer view of how the top and bottom lines are tracking into this latest quarter...

Wondering if Rockwool at a last close of DKK 185.8 is starting to look attractive, or if the price still does not quite line up with the underlying business. The stock has been choppy, with a 4.7% decline over the last 7 days, a 6.3% gain over 30 days, and longer-term returns of a 17.2% decline year to date and a 35.4% decline over 1 year, while the 3-year return sits at 19.9% and the 5-year return at a 24.0% decline. Recent coverage around Rockwool has focused on how the share price path...

If you are wondering whether AL Sydbank at around kr.544.50 is still offering value or if most of the opportunity is already priced in, you are in the right place. The share price has moved around recently, with a 3% decline over the last 7 days, an 8.4% gain over the last 30 days, a 4.6% decline year to date, and a 37.2% return over the past year, capped by very large gains over 3 and 5 years. These swings have been accompanied by ongoing interest in the Danish banking sector and investor...

If you are wondering whether DSV’s current share price reflects its underlying value, this article walks through the key signals that matter for valuation focused investors. Over the past year, DSV has returned 29.8%, with moves like an 11.2% return over the last 30 days and a 2.3% decline over the last week, which may hint at changing sentiment and risk appetite. Recent evergreen coverage interest has kept attention on how DSV is priced versus fundamentals, and has brought valuation back...

ISS has recently expanded its partnership with the Fulham Road Collaborative in the UK, securing a five-year, approximately DKK 100 million per year contract to provide integrated facility services across three major hospital sites, while also deepening its global workplace technology offering through a new partnership with Sign In Solutions. Together, the enlarged UK healthcare contract and the integration of Sign In Solutions into ISS’s Convenie platform highlight the group’s push to...

Wondering if Novo Nordisk at DKK 265.8 still offers value, or if the best opportunity is already behind you? This article walks through what the current price actually reflects. The stock has moved sharply in the short term, with a 7.6% return over 7 days and 16.3% over 30 days, set against a year to date return of 19.5% decline and a 34.5% decline over the last year. These swings sit in the context of ongoing attention on Novo Nordisk's role in global pharmaceuticals, including regular...

Why Københavns Lufthavne Is On Investors’ Radar Københavns Lufthavne (CPSE:KBHL) has come into focus after a recent spell of weaker share performance, with negative returns over the past month, past 3 months and year prompting closer attention to its fundamentals. See our latest analysis for Københavns Lufthavne. With the share price at DKK5,880, Københavns Lufthavne has recorded a 6.67% decline over the past month and a 14.04% year-to-date share price retreat, alongside a 10.64% one-year...

For investors wondering whether ALK-Abelló’s current share price reflects its real worth or whether the market is getting ahead of itself, this breakdown focuses squarely on what you are paying versus what you are getting. With the stock at DKK 229.2 and returns of 2.7% over 7 days, 13.5% over 30 days, 1.1% year to date, 59.1% over 1 year, 167.0% over 3 years and 73.6% over 5 years, recent performance provides important context for any valuation view. Recent attention around ALK-Abelló has...

Vestas Wind Systems (CPSE:VWS) has attracted fresh attention after securing a 70 MW order from Tessa Green Energy for Bulgaria’s Strazhitsa wind project, paired with a long-term Active Output Management 5000 service agreement. See our latest analysis for Vestas Wind Systems. The new Bulgaria contract lands as Vestas’ share price trades at DKK192.0, with a 1 month share price return of 9.18% and a 1 year total shareholder return of 118.53%. This points to recent momentum following a mixed 3...

Why Carlsberg’s expanded PepsiCo partnership matters for shareholders Carlsberg (CPSE:CARL B) has agreed to expand its long running collaboration with PepsiCo, taking over bottling in Denmark, Finland and the Baltic states from 2029 as existing Coca-Cola arrangements conclude. For you as an investor, this shift means Carlsberg is set to handle production, sales and distribution of PepsiCo drinks across all Nordic markets, plus Latvia, Estonia and Lithuania. That extends an arrangement that...